| 1.835 -0.155 (-7.79%) | 04-20 11:11 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.51 | 1-year : | 2.93 |
| Resists | First : | 2.15 | Second : | 2.51 |
| Pivot price | 1.82  |
|||
| Supports | First : | 1.65 | Second : | 1.35 |
| MAs | MA(5) : | 1.96 |
MA(20) : | 1.74 |
| MA(100) : | 1.8 |
MA(250) : | 1.99 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 72.8 |
D(3) : | 76.5 |
| RSI | RSI(14): 55.6 |
|||
| 52-week | High : | 3.09 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PRQR ] has closed below upper band by 37.4%. Bollinger Bands are 21.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.06 - 2.07 | 2.07 - 2.09 |
| Low: | 1.93 - 1.95 | 1.95 - 1.96 |
| Close: | 1.97 - 1.99 | 1.99 - 2.01 |
ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. It primarily develops sepofarsen that is in phase II/III clinical trial illuminate trial for treating leber congenital amaurosis 10 disease; and ultevursen, which is in phase II/III clinical trial to treat USH2A-mediated retinitis pigmentosa and usher syndrome. The company also engages in the developing of Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center, Inserm Transfert SA, Ionis Pharmaceuticals, Inc., and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. ProQR Therapeutics N.V. was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
Sat, 11 Apr 2026
If You Invested $1,000 in Proqr Therapeuti (PRQR) - Stock Titan
Fri, 10 Apr 2026
ProQR Therapeutics: Waiting On Proof As AX-0810 Data Approaches (NASDAQ:PRQR) - Seeking Alpha
Thu, 09 Apr 2026
Aberdeen Group plc Has $5.96 Million Holdings in ProQR Therapeutics N.V. $PRQR - MarketBeat
Wed, 08 Apr 2026
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board - GlobeNewswire
Wed, 08 Apr 2026
ProQR Therapeutics N.V. (PRQR) Shareholder/Analyst Call - Slideshow (NASDAQ:PRQR) 2026-04-08 - Seeking Alpha
Wed, 25 Mar 2026
ProQR (PRQR) schedules April 8 virtual event on Axiomer RNA pipeline - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 105 (M) |
| Shares Float | 64 (M) |
| Held by Insiders | 17.6 (%) |
| Held by Institutions | 50.7 (%) |
| Shares Short | 1,670 (K) |
| Shares Short P.Month | 1,700 (K) |
| EPS | -0.47 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.55 |
| Profit Margin | -258.1 % |
| Operating Margin | -192.9 % |
| Return on Assets (ttm) | -19.4 % |
| Return on Equity (ttm) | -61.2 % |
| Qtrly Rev. Growth | 6 % |
| Gross Profit (p.s.) | 0.15 |
| Sales Per Share | 0.15 |
| EBITDA (p.s.) | -0.41 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -53 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -4.04 |
| PEG Ratio | 0 |
| Price to Book value | 3.44 |
| Price to Sales | 12.21 |
| Price to Cash Flow | -3.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|